HGH Fragment 176-191

Cited range

ClassGH C-terminal fragment

Typical routes in papersSC

Half-life contextShort

EvidenceMixed clinical attempts; community use

What it is

A lab-cut piece of growth hormone’s tail that researchers hoped would keep GH’s fat-releasing trick without the growth and glucose baggage. AOD-9604 is a stabilized relative already in this library.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

The intended benefit is help releasing stored fat, especially when paired with a deficit and walking.
It should not act like full GH for muscle or IGF-1. That is the design pitch.
Results in formal studies were not a slam dunk, which is why it never became a standard drug.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Proposed stimulation of lipolysis and inhibition of lipogenesis via GH-fragment pathways that spare GH-receptor growth signaling.

Possible side effects / caveats

Injection-site issues, headaches in anecdotes, and disappointment if diet is unchanged.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Cited range	250–500 mcg	1–2× daily, often fasted AM	Common secondary-source range
Related	AOD-9604	Stabilized analog	See that monograph

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.